Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint for SINTBILO
FROM THE WIRE · FINANCE.YAHOO.COM
SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4W SINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive clinical result for a Hong Kong-listed biotech, relevant for the pharma sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01SINTBILO monotherapy reduced mean LDL-C by over 60% after 12 weeks.
- 02The treatment also significantly decreased non-HDL-C, vLDL-C, ApoB and Lp(a).
- 03No new safety signals were identified.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Innovent Biologics, Inc.87.05 HKD+0.81%today +0.81%Positive Shanghai Henlius Biotech, Inc.50.40 HKD+2.82%today +2.82%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets